Zollinger‑Ellison Syndrome – MEN2‑Associated
Overview
Zollinger‑Ellison syndrome (ZES) is a rare disorder characterized by one or more gastrin‑producing tumors (gastrinomas) that cause excessive gastric acid secretion. When ZES occurs as part of multiple endocrine neoplasia type 2 (MEN2), it is termed MEN2‑associated ZES. MEN2 is an inherited cancer‑predisposition syndrome that also includes medullary thyroid carcinoma, pheochromocytoma, and hyperparathyroidism (in MEN2A).
Who it affects: MEN2 is caused by germline mutations in the RET proto‑oncogene. About 25‑30 % of individuals with MEN2 develop gastrinomas, and most of these present with ZES. The condition typically manifests in the third to fifth decade of life, but because MEN2 is hereditary, family members can be diagnosed in childhood through genetic testing.
Prevalence: Isolated ZES occurs in ≈1–3 per million people. MEN2 occurs in ≈1 in 30,000–40,000 live births, and gastrinomas develop in roughly 10–30 % of those patients, making MEN2‑associated ZES an ultra‑rare condition (≈0.3–1 per million).1, 2
Symptoms
Excess gastric acid leads to a characteristic constellation of gastrointestinal and systemic signs. The severity varies with tumor burden and acid output.
- Refractory peptic ulcer disease – ulcers in atypical locations (duodenum distal to the bulb, jejunum, or even the stomach) that do not heal with standard therapy.
- Abdominal pain – often epigastric, worsening 1–2 h after meals due to acid‑induced mucosal injury.
- Chronic diarrhea – acidic chyme inactivates pancreatic enzymes and damages the intestinal mucosa, leading to watery, sometimes fatty stools.
- Heartburn / gastro‑esophageal reflux disease (GERD) – due to massive acid load.
- Nausea & vomiting – especially when ulcer disease is severe.
- Weight loss – secondary to malabsorption and chronic diarrhea.
- Gastric hyperplasia – enlarged gastric folds seen on endoscopy.
- Bleeding – melena or hematemesis from ulcer erosion.
- Fatigue & anemia – chronic blood loss or iron deficiency.
- Symptoms related to other MEN2 tumors – e.g., episodic headaches, palpitations (pheochromocytoma) or a neck mass (medullary thyroid carcinoma). Recognizing these co‑existing conditions is essential for comprehensive care.
Causes and Risk Factors
Genetic Basis
MEN2‑associated ZES results from inherited activating mutations in the RET proto‑oncogene located on chromosome 10q11.2. Different RET mutations confer variable risk for specific MEN2 manifestations:
- MEN2A (mutations at codons 634, 620, 618, 609) – highest risk for gastrinomas (≈20‑30 %).
- MEN2B (mutation at codon 918) – gastrinomas are less common, but acid hypersecretion may still occur.
These mutations are autosomal dominant; each child of an affected individual has a 50 % chance of inheriting the mutation.
Other Risk Factors
- Family history of MEN2 – the strongest predictor.
- Presence of other MEN2 tumors – especially medullary thyroid carcinoma.
- Age – most gastrinomas become clinically apparent between 30 and 50 years.
There are no known lifestyle or environmental risk factors for MEN2‑associated ZES.
Diagnosis
Because symptoms mimic common gastrointestinal disorders, a high index of suspicion is needed, especially in patients with a known RET mutation.
Biochemical Testing
- Fasting serum gastrin – levels >1,000 pg/mL are highly suggestive; values 2–10 × the upper limit of normal with a gastric pH < 2 are diagnostic.
- Secretin stimulation test – paradoxical rise in gastrin after intravenous secretin (≥120 pg/mL increase) confirms ZES.
- Gastric pH measurement – low pH (<2) despite high gastrin supports acid hypersecretion.
Imaging Studies
- Endoscopic ultrasound (EUS) – highly sensitive for small pancreatic or duodenal gastrinomas.
- Multiphasic contrast‑enhanced CT or MRI – evaluates tumor size, location, and metastasis (especially liver).
- Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – detects occult or metastatic lesions that express somatostatin receptors.
Genetic Testing
All patients with ZES should undergo RET mutation analysis if not already performed. Positive results confirm MEN2 and trigger cascade testing for relatives.
Histopathology
When surgery is performed, tissue is examined for neuroendocrine features (chromogranin A, synaptophysin positivity) and Ki‑67 index to grade tumor aggressiveness.
Treatment Options
Management combines acid suppression, tumor control, and surveillance for other MEN2 manifestations.
Acid‑Suppression Therapy (First‑line)
- High‑dose Proton Pump Inhibitors (PPIs) – omeprazole 60 mg/day, esomeprazole 40 mg/day, or pantoprazole 80 mg/day, adjusted to maintain gastric pH > 4. Long‑term use is generally safe but requires monitoring for magnesium, vitamin B12, and calcium deficiencies.
- Histamine‑2 receptor antagonists (H2RAs) – less effective alone; may be used adjunctively.
Surgical Management
Curative resection is the goal when tumors are localized.
- Enucleation or distal pancreatectomy for solitary gastrinomas.
- Whipple procedure (pancreaticoduodenectomy) for larger or multiple duodenal lesions.
- Liver metastasectomy or ablative therapies if hepatic spread is limited.
Because many gastrinomas are small (<2 cm) and multifocal, complete resection can be challenging. Multidisciplinary surgical planning is essential.
Medical Therapies for Unresectable or Metastatic Disease
- Somatostatin analogs (octreotide LAR or lanreotide) – suppress gastrin secretion and may stabilize tumor growth.
- Targeted therapy – everolimus (mTOR inhibitor) is FDA‑approved for advanced neuroendocrine tumors.
- Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE for somatostatin‑receptor positive disease.
- Chemotherapy (streptozocin‑based regimens) – reserved for aggressive, rapidly progressive tumors.
Management of Other MEN2 Tumors
Prophylactic thyroidectomy is recommended for RET mutation carriers (usually before age 5 in MEN2B, before age 10 in MEN2A). Pheochromocytoma should be screened annually with plasma metanephrines and treated before any abdominal surgery.
Lifestyle & Supportive Measures
- Avoid NSAIDs, aspirin, and other ulcerogenic medications.
- Limit alcohol and caffeine, which increase acid production.
- Adopt a low‑fat, high‑protein diet if diarrhea is prominent.
- Maintain adequate hydration and replace electrolytes (magnesium, potassium) as needed.
Living with Zollinger‑Ellison Syndrome – MEN2‑Associated
Daily Management Tips
- Medication adherence – take PPIs exactly as prescribed; never skip doses.
- Regular monitoring – check serum gastrin and vitamin/mineral levels every 6–12 months.
- Endoscopic surveillance – upper endoscopy every 1–2 years to assess ulcer healing and detect new lesions.
- Genetic counseling – ensure family members are tested and receive appropriate surveillance.
- Psychosocial support – join MEN2 support groups; chronic disease can affect mental health.
- Vaccinations – patients on long‑term PPIs may have a slightly increased risk of C. difficile; maintain up‑to‑date immunizations, especially for influenza and COVID‑19.
Follow‑up Schedule
| Visit Type | Frequency | Key Assessments |
|---|---|---|
| Endocrinology | Every 6 months | Gastrin level, PPI dose, symptom questionnaire |
| Gastroenterology | Every 12–24 months | Endoscopy, biopsies if ulcer persists |
| Oncology (if metastatic) | Every 3–6 months | Imaging (CT/MRI or PET), PRRT/targeted therapy response |
| Genetics | At diagnosis, then as needed | Family testing results, counseling updates |
Prevention
Because MEN2‑associated ZES is genetic, primary prevention is not possible. However, secondary prevention strategies can mitigate disease impact:
- Early genetic testing of at‑risk relatives and timely prophylactic thyroidectomy.
- Routine surveillance for gastrin levels and abdominal imaging beginning in adolescence for mutation carriers.
- Lifestyle measures that reduce gastric irritation (avoid tobacco, limit alcohol, use ulcer‑friendly medications).
Complications
If left untreated or inadequately controlled, ZES can lead to serious health problems:
- Recurrent, perforated peptic ulcer – can cause peritonitis and require emergency surgery.
- Gastrointestinal bleeding – chronic blood loss may lead to iron‑deficiency anemia.
- Severe malabsorption – chronic diarrhea can cause weight loss, electrolyte disturbances, and osteoporosis.
- Gastric carcinoids – prolonged hypergastrinemia stimulates enterochromaffin‑like cell proliferation.
- Liver metastases – common in gastrinomas; may cause hepatic failure.
- Compounded MEN2 issues – pheochromocytoma crisis or medullary thyroid carcinoma progression.
When to Seek Emergency Care
- Sudden, severe abdominal pain with a rigid, board‑like abdomen (possible perforated ulcer).
- Profuse vomiting or vomiting of blood (hematemesis).
- Black, tarry stools or a sudden drop in hemoglobin (signs of major gastrointestinal bleed).
- Rapid heart rate, high blood pressure, severe headache, sweating, or panic‑like symptoms in a known MEN2 patient (possible pheochromocytoma crisis).
- Persistent diarrhea (>5 watery stools per day) with signs of dehydration (dry mouth, dizziness, low urine output).
Prompt treatment can be life‑saving.
**References**
- Mayo Clinic. “Zollinger-Ellison syndrome.” https://www.mayoclinic.org. Accessed May 2026.
- CDC Genetics Home Reference. “Multiple endocrine neoplasia type 2 (MEN2).” https://www.cdc.gov. Accessed May 2026.
- NIH National Cancer Institute. “Neuroendocrine Tumors Treatment (PDQ®) – Health Professional Version.” https://www.cancer.gov. Updated 2024.
- Cleveland Clinic. “MEN2 (Multiple Endocrine Neoplasia Type 2).” https://my.clevelandclinic.org. Accessed May 2026.
- World Health Organization. “Classification of Neuroendocrine Tumors.” WHO Classification of Tumours, 5th ed., 2022.